NO20091057L - Oral form of birth control - Google Patents

Oral form of birth control

Info

Publication number
NO20091057L
NO20091057L NO20091057A NO20091057A NO20091057L NO 20091057 L NO20091057 L NO 20091057L NO 20091057 A NO20091057 A NO 20091057A NO 20091057 A NO20091057 A NO 20091057A NO 20091057 L NO20091057 L NO 20091057L
Authority
NO
Norway
Prior art keywords
birth control
dienogest
oral form
less
daily dose
Prior art date
Application number
NO20091057A
Other languages
Norwegian (no)
Inventor
Herbert Wiesinger
Hagen Gerecke
Sabine Fricke
Ralf Ladwig
Alexander Buske
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20091057L publication Critical patent/NO20091057L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Oral legemiddelform for prevensjon omfatter som en aktiv forbindelse, 17a-cyanometyl-17-ß-hydroksyøstra-4,9-dien-3-on (dienogest) i en daglig dose lik eller mindre enn 2,0 mg og som annen aktiv komponent 17a-etynyløstradiol (etynyløstradiol) i en daglig dose på mindre enn 0,03 mg, sammen med én eller flere farmasøytisk akseptable bærere. Den aktive bestanddel dienogest er til stede i krystallinsk form med en midlere partikkelstørrelse på fra 25 til 70 µm. Den aktive bestanddel etynyløstradiol er innført i mikronisert form eller som etanolisk løsning under granuleringen.Oral form of birth control comprises, as an active compound, 17α-cyanomethyl-17-β-hydroxyester-4,9-dien-3-one (dienogest) in a daily dose equal to or less than 2.0 mg and as another active component 17a -ethynyl estradiol (ethynyl estradiol) at a daily dose of less than 0.03 mg, together with one or more pharmaceutically acceptable carriers. The active ingredient dienogest is present in crystalline form with an average particle size of from 25 to 70 µm. The active ingredient ethynyl oestradiol is introduced in micronized form or as ethanolic solution during the granulation.

NO20091057A 2006-08-10 2009-03-09 Oral form of birth control NO20091057L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06016694A EP1886694B1 (en) 2006-08-10 2006-08-10 Peroral formulation of dienogest and ethinylestradiol for contraception
PCT/EP2007/003662 WO2008017331A2 (en) 2006-08-10 2007-04-26 Peroral drug form comprising dienogest and ethinyl estradiol for contraception

Publications (1)

Publication Number Publication Date
NO20091057L true NO20091057L (en) 2009-03-09

Family

ID=37561777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091057A NO20091057L (en) 2006-08-10 2009-03-09 Oral form of birth control

Country Status (18)

Country Link
EP (1) EP1886694B1 (en)
AR (1) AR062323A1 (en)
AT (1) ATE432714T1 (en)
CL (1) CL2007002323A1 (en)
CY (1) CY1110348T1 (en)
DE (1) DE502006003892D1 (en)
DK (1) DK1886694T3 (en)
DO (1) DOP2007000122A (en)
ES (1) ES2327665T3 (en)
HR (1) HRP20090438T1 (en)
NO (1) NO20091057L (en)
PE (1) PE20080541A1 (en)
PL (1) PL1886694T3 (en)
PT (1) PT1886694E (en)
SI (1) SI1886694T1 (en)
TW (1) TW200817012A (en)
UY (1) UY30530A1 (en)
WO (1) WO2008017331A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010003711B4 (en) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Process for the preparation of crystalline active substance particles
CN115487198B (en) * 2022-09-20 2024-01-02 华中药业股份有限公司 Levonorgestrel preparation with fast dissolution rate and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE10218107A1 (en) * 2002-04-23 2003-11-20 Jenapharm Gmbh Process for the production of crystals of steroids, crystals available thereafter and their use in pharmaceutical formulations

Also Published As

Publication number Publication date
ATE432714T1 (en) 2009-06-15
DOP2007000122A (en) 2008-02-15
TW200817012A (en) 2008-04-16
PE20080541A1 (en) 2008-07-10
DE502006003892D1 (en) 2009-07-16
UY30530A1 (en) 2008-03-31
CY1110348T1 (en) 2015-04-29
HRP20090438T1 (en) 2009-09-30
DK1886694T3 (en) 2009-09-28
PT1886694E (en) 2009-08-17
WO2008017331A3 (en) 2009-01-08
AR062323A1 (en) 2008-10-29
ES2327665T3 (en) 2009-11-02
SI1886694T1 (en) 2009-10-31
PL1886694T3 (en) 2009-11-30
CL2007002323A1 (en) 2008-02-15
EP1886694B1 (en) 2009-06-03
WO2008017331A2 (en) 2008-02-14
EP1886694A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
NZ602698A (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
JP2008540482A5 (en)
JP2010180236A5 (en)
EA200900491A1 (en) USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN
WO2007106264A3 (en) Extended cycle multiphasic oral contraceptive method
NZ605176A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
CA2608639A1 (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
WO2007021805A3 (en) Estrogen compositions and therapeutic methods of use thereof
KR20000022189A (en) Progestogen-anti-progestogen regimens
HRP20240121T1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
AR061959A1 (en) PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS
NO327588B1 (en) Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive
NO20056153L (en) Preparation comprising antiprogestins and pure antiostrogens for prophylaxis and treatment of hormone-dependent diseases
NO20091057L (en) Oral form of birth control
EA200701389A1 (en) SOLID ORAL MEDICAL FORM FOR CONTRACEPTION
NO20072687L (en) Pharmaceutical contraceptive preparation
TW200731977A (en) Use of estradiol valerate in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception
EA200900829A1 (en) PHARMACEUTICAL PREPARATION FOR REDUCING ENDOMETRIOSIS
UY29378A1 (en) PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION
PE20091020A1 (en) USE OF A GESTAGEN IN COMBINATION WITH A ESTROGEN AND ONE OR MORE PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS / CARRIERS FOR LACTOSE-FREE ORAL CONTRACEPTION
HRP20200155T1 (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
SI1937274T1 (en) Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
TH80558A (en) Solid oral dosage forms for birth control
TH54054B (en) Pharmaceutical mixtures for use as birth control pills
TH80557B (en) Pharmaceutical products for oral contraception

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application